• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    4/11/23 12:47:36 PM ET
    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Telecommunications Equipment
    Utilities
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $ADTN alert in real time by email

    Gainers

    • Innovative Eyewear, Inc. (NASDAQ:LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear.
    • National CineMedia, Inc. (NASDAQ:NCMI) climbed 81% to $0.2409 after a 13G filing showed a 9.1% passive stake in the company from AMC Entertainment.
    • IMAC Holdings, Inc. (NASDAQ:BACK) gained 71% to $0.2144. IMAC Holdings and Brain Scientific recently announced a strategic merger to create a synergistic end-to-end neurological solution.
    • WW International, Inc. (NASDAQ:WW) shares jumped 48.9% to $6.14 after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $3.8 to $13.
    • ZeroFox Holdings, Inc. (NASDAQ:ZFOX) gained 47.4% to $2.44 after the company announced it partnered with Google Cloud to disrupt phishing attacks and malicious URLs.
    • Clearmind Medicine Inc. (NASDAQ:CMND) gained 35.4% to $0.5818 after jumping more than 10% on Monday.
    • Silvergate Capital Corporation (NYSE:SI) surged 33% to $1.85.
    • Apollomics, Inc. (NASDAQ:APLM) jumped 30.5% to $10.62.
    • Brookdale Senior Living Inc. (NYSE:BKD) shares gained 23.8% to $3.6899 after the company reported favorable updates to its Q1 financial expectations based upon preliminary, unaudited results.
    • VBI Vaccines Inc. (NASDAQ:VBIV) jumped 23.8% to $0.1696.
    • Nogin, Inc. (NASDAQ:NOGN) gained 22.6% to $2.17 following insider buying.
    • BTCS Inc. (NASDAQ:BTCS) jumped 21.6% to $1.3871.
    • Cognyte Software Ltd. (NASDAQ:CGNT) gained 21% to $4.14 after reporting upbeat Q4 results.
    • SciSparc Ltd. (NASDAQ:SPRC) rose 17.2% to $0.5619.
    • BigBear.ai Holdings, Inc. (NYSE:BBAI) gained 15% to $3.23.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) jumped 14.5% to $3.0350. ReShape Lifesciences received a Notice of Allowance for US Patent related to its Obalon Balloon System.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) gained 14.2% to $21.71.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) rose 13.8% to $0.5127
    • Alpha Teknova, Inc. (NASDAQ:TKNO) surged 12.2% to $2.7050. Alpha Teknova recently posted better-than-expected quarterly results.
    • PriceSmart, Inc. (NASDAQ:PSMT) gained 10.5% to $78.19 following better-than-expected Q2 results.
    • Butterfly Network, Inc. (NYSE:BFLY) gained 10.1% to $2.72.
    • CarMax, Inc. (NYSE:KMX) jumped 9.9% to $72.43 after the company reported Q4 financial results and affirmed long-term financial targets.
    • Brenmiller Energy Ltd (NASDAQ:BNRG) gained 9.6% to $1.48 after gaining more than 44% on Monday.
    • eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) rose 8.8% to $0.3951. eFFECTOR Therapeutics will collaborate with Stanford Medicine on an investigator-initiated randomized Phase 2 study evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a preoperative setting.
    • Centogene N.V. (NASDAQ:CNTG) surged 7.7% to $0.7003. Centogene extended partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs).
    • Dada Nexus Limited (NYSE:DADA) gained 7.1% to $7.86.

    Losers

    • PLx Pharma Inc. (NASDAQ:PLXP) fell 48.5% to $0.1861. PLx Pharma received a written notice from Nasdaq Listing Qualifications Department.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) dipped 41% to $3.89. Professional Diversity Network recently acquired additional 20% stake in RemoteMore USA.
    • Kalera Public Limited Company (NASDAQ:KAL) dropped 36.8% to $1.70 after the company received a notice of delisting form Nasdaq.
    • GlucoTrack, Inc. (NASDAQ:GCTK) shares fell 32.5% to $2.16 after surging 169% on Monday.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 29.2% to $0.1186. Virgin Orbit announced receipt of Nasdaq delisting notice after filing for bankruptcy.
    • HEXO Corp. (NASDAQ:HEXO) fell 26.2% to $1.2109 after the company announced acquisition by Tilray Brands.
    • ADTRAN Holdings, Inc. (NASDAQ:ADTN) fell 24.5% to $11.41 after the company announced preliminary results for Q1 2023. The company expects preliminary revenue to be between $322 million and $326 million as compared to its guidance of $355 million to $375 million.
    • Agrify Corporation (NASDAQ:AGFY) fell 24% to $0.2121 after jumping over 95% on Monday.
    • Blue Safari Group Acquisition Corp. (NASDAQ:BSGA) dropped 23.7% to $9.10.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) fell 23.3% to $1.22. SMX recently formed a task force to investigate past trading patterns.
    • Office Properties Income Trust (NASDAQ:OPI) shares dropped 22.9% to $8.90. Office Properties Income Trust agreed to acquire all outstanding common shares of Diversified Healthcare Trust in an all-share transaction.
    • Glory Star New Media Group Holdings Limited (NASDAQ:GSMG) dipped 21.8% to $0.5117. Glory Star New Media Group reports termination of merger agreement dated July 11, 2022.
    • Akanda Corp. (NASDAQ:AKAN) dropped 20.3% to $1.02.
    • D-Wave Quantum Inc. (NYSE:QBTS) fell 18.8% to $0.6901.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) dropped 16.4% to $8.62. Agile Therapeutics announced a 1-for-50 reverse stock split.
    • Uxin Limited (NASDAQ:UXIN) fell 16% to $2.05 following weak quarterly sales.
    • HeartBeam, Inc. (NASDAQ:BEAT) declined 15.5% to $1.9840. HeartBeam filed for offering of up to 16.7 million shares of common stock.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) shares fell 14.9% to $0.0698 after dropping around 9% on Monday.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) fell 9% to $0.5280.
    • Tilray Brands, Inc. (NASDAQ:TLRY) fell 6.4% to $2.5650 after the company reported third-quarter financial results and announced its acquisition plans for Canadian cannabis producer Hexo.

    Now Read This: Bitcoin Jumps Above $30,000 Ahead Of Inflation Data; Render Token Emerges As Top Gainer

    Get the next $ADTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTN
    $AGFY
    $AGRX
    $AKAN

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    3/27/2026$5.00Buy
    D. Boral Capital
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    D-Wave Quantum Inc.
    $QBTS
    2/12/2026Buy
    TD Cowen
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    BigBear.ai Inc.
    $BBAI
    1/7/2026$6.00Overweight → Neutral
    Cantor Fitzgerald
    Brookdale Senior Living Inc.
    $BKD
    1/6/2026$13.00Underperform → Buy
    BofA Securities
    D-Wave Quantum Inc.
    $QBTS
    12/17/2025$35.00Outperform
    Wedbush
    D-Wave Quantum Inc.
    $QBTS
    12/11/2025$46.00Outperform
    Mizuho
    More analyst ratings

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ricker Sean Raymond

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    3/27/26 4:35:26 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Blankenship Carolyn

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    3/27/26 4:34:29 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Mcaleenan Kevin

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    3/27/26 4:33:43 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    SEC Filings

    View All

    SEC Form S-8 filed by BTCS Inc.

    S-8 - BTCS Inc. (0001436229) (Filer)

    3/27/26 5:04:25 PM ET
    $BTCS
    Finance: Consumer Services
    Finance

    SEC Form 144 filed by National CineMedia Inc.

    144 - National CineMedia, Inc. (0001377630) (Subject)

    3/27/26 4:39:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.

    SCHEDULE 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    3/27/26 1:34:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

    RUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during Q2 of 2026. "In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring tec

    3/27/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    BTCS Reports 305% Year-Over-Year Revenue Growth to Record $16.5 Million for Full Year 2025

    WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (NASDAQ:BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure and decentralized finance operations, today announced its financial results for the year ended December 31, 2025 ("FY 2025"). The Company also released an updated investor presentation available at www.btcs.com/investors/. "2025 was a transformative year for BTCS as we scaled our Ethereum-first operating model and delivered record revenue," said Charles Allen, Chief Executive Officer of BTCS. "Revenue grew over 300%, driven by the expansion of Builder+, our block-building business, and the succ

    3/27/26 8:00:00 AM ET
    $BTCS
    Finance: Consumer Services
    Finance

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO & Executive Chairman Ball Robert Joseph bought $33,392 worth of shares (2,200 units at $15.18), increasing direct ownership by 0.80% to 278,866 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:31:09 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on HeartBeam with a new price target

    D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

    3/27/26 8:50:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded HeartBeam from Buy to Speculative Buy and set a new price target of $8.00

    3/16/26 8:51:28 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on D-Wave Quantum

    TD Cowen initiated coverage of D-Wave Quantum with a rating of Buy

    2/12/26 7:24:12 AM ET
    $QBTS
    EDP Services
    Technology

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Leadership Updates

    Live Leadership Updates

    View All

    Starboard Delivers Letter to CarMax

    Views Appointment of New CEO Keith Barr as Timely Opportunity to Address Fixable Execution Gaps and Unlock CarMax's Full Value Potential Has Nominated Directors to Help Support the Next Phase of Execution and Accelerate Shareholder Value Creation Believes CarMax's Structurally Superior Omnichannel Model Is Not Reflected in Current Performance Sees Clear Opportunities to Drive Improvement Through Enhanced Digital Execution, Reconditioning Efficiencies and Dynamic Pricing Urges a Substantially Expanded SG&A Reduction Program to Restore Cost Discipline and Enhance Long-Term Earnings Power Starboard Value LP (together with its affiliates, "Starboard"), a significant stockholder of Car

    3/11/26 8:00:00 AM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Financials

    Live finance-specific insights

    View All

    BTCS Reports 305% Year-Over-Year Revenue Growth to Record $16.5 Million for Full Year 2025

    WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (NASDAQ:BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure and decentralized finance operations, today announced its financial results for the year ended December 31, 2025 ("FY 2025"). The Company also released an updated investor presentation available at www.btcs.com/investors/. "2025 was a transformative year for BTCS as we scaled our Ethereum-first operating model and delivered record revenue," said Charles Allen, Chief Executive Officer of BTCS. "Revenue grew over 300%, driven by the expansion of Builder+, our block-building business, and the succ

    3/27/26 8:00:00 AM ET
    $BTCS
    Finance: Consumer Services
    Finance

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Cognyte Reports Fourth Quarter and Fiscal Year 2026 Financial Results

    Reports strong Q4 and full-year results with double-digit growth, and operating leverage driving faster profitability growth Guides to fiscal 2027 revenue of approximately $448 million with additional margin expansion Cognyte Software Ltd. (NASDAQ:CGNT) (the "Company," "Cognyte," "we," "us" and "our"), a global leader in software-driven technology for investigative analytics, today announced results for the three months and year ended January 31, 2026 ("Q4 FYE26" and "FYE26"). Financial Summary for Three Months Ended January 31, 2026 Q4 FYE26 Revenue was $106.2 million, up approximately 12.4% compared to the same period last year. Q4 FYE26 GAAP operating income was $5.2 million,

    3/25/26 7:05:00 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    $ADTN
    $AGFY
    $AGRX
    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Office Properties Income Trust

    SC 13G - OFFICE PROPERTIES INCOME TRUST (0001456772) (Subject)

    12/17/24 8:04:10 PM ET
    $OPI
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology